drugset / Trial / NCT02473458

Efficacy of Whole Extract of Licorice in Neurological Improvement of Patients After Acute Ischemic Stroke

NCT02473458 ↗

Phase 1/2 Completed 75 enrolled Shiraz University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Stroke is one of the most important causes of mortality and disability both in developed and developing countries. The only food and drug administration (FDA) approved therapy for acute stroke is recombinant tissue plasminogen activator (rtPA). But narrow therapeutic window has limited the usefulness of thrombolytic therapy. Therefore, finding effective neuroprotective drugs for the patients for whom thrombolysis is contraindicated or not feasible seemed to be mandatory in the world of cerebrovascular medicine. Licorice, extracted from root of a plant scientifically known as Glycyrrhiza glabra, is used in food industries. Certain medical properties has been contributed to licorice and specifically to its active chemical components such as flavonoids and glycyrrhizic acid (GA). GA has been revealed to assert its anti-inflammatory effect by suppression of NF-κB, a key component of lipopolysaccharide-induced inflammatory response. Neuroprotective characteristics of GA has been widely investigated in recent studies. In the present study, the investigators verified the efficacy and safety of oral administration of two different doses licorice extract in the patients with acute ischemic stroke, in a double-blind randomized controlled trial.

Timeline

Start
2012-06
Primary completion
2013-06
Completion
2014-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Licorice whole extract Unknown 450 mg Oral
Subject Licorice whole extract Unknown 900 mg Oral

Indications